In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
|Articles|December 21, 2009
Medical Website: AGA Member Perspectives
This opinion forum serves as a venue in which noted names in gastroenterology can publicly discuss and debate topical issues of importance in the specialty.
Advertisement
This opinion forum serves as a venue in which noted names in gastroenterology can publicly discuss and debate topical issues of importance in the specialty; AGA Perspectives is published once every two months, although there have been no new Perspectives for 2006. Sample titles of recent editions include “The Propofol Debate,” “Colorectal Cancer Screening,” and “Does Bacterial Outgrowth Play a Role in IBS?”
To access this third-party resoruce, click
Advertisement
Related to this article
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial
4
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
5